AI Article Synopsis
- The traditional step-up approach for treating Crohn's disease begins with milder medications like 5-aminosalicylic acid and moves to stronger drugs like corticosteroids and biologics as needed.
- A newer top-down approach emphasizes starting treatment with biologics and immunomodulators earlier to minimize mucosal and intestinal damage.
- This article discusses the benefits of early aggressive therapy compared to the standard step-up method for managing Crohn's disease.
Article Abstract
Traditionally, medical providers have used the step-up approach to manage patients with Crohn disease, starting with 5-aminosalicylic acid derivatives, progressing to corticosteroids, and eventually to immunomodulators and biologics. However, a new top-down approach focuses on early and aggressive therapy with biologics and immunomodulators to reduce the rate of mucosal and intestinal damage. This article describes early and aggressive biologic and immunomodulator therapies and new therapeutic parameters compared with traditional step-up treatment for patients with Crohn disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JAA.0000000000000013 | DOI Listing |
Publication Analysis
Top Keywords
early aggressive
12
crohn disease
12
biologics immunomodulators
8
patients crohn
8
aggressive treatment
4
treatment crohn
4
disease biologics
4
immunomodulators traditionally
4
traditionally medical
4
medical providers
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!